Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series.

Alzheimer Dis Assoc Disord

*Department of Neurology and Psychiatry †Taub Institute for Research on Alzheimer's Disease and the Aging Brain ‡Sergievsky Center §Division of Geriatric Psychiatry, New York State Psychiatric Institute ∥Columbia University Medical Center, New York, NY.

Published: June 2018

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322244PMC
http://dx.doi.org/10.1097/WAD.0000000000000161DOI Listing

Publication Analysis

Top Keywords

low-dose lithium
4
lithium treatment
4
treatment agitation
4
agitation psychosis
4
psychosis alzheimer
4
alzheimer disease
4
disease frontotemporal
4
frontotemporal dementia
4
dementia case
4
case series
4

Similar Publications

Epilepsy is a common brain function disorder. The present study aims to evaluate the long-term effect of perampanel (PRM) and lacosamide (LCM), administered singly in a high-dose or in a low-dose combination of both, on comorbid anxiety, cognitive impairment, BDNF, and Cyclin D1 hippocampal expression in an experimental model of temporal lobe epilepsy with lithium-pilocarpine. PRM (3 mg/kg, p.

View Article and Find Full Text PDF

Refractory status epilepticus (RSE) is a condition with serious mortality and morbidity rate, resistant to benzodiazepine and second-line antiepileptic drugs. This study aimed to electrophysiologically investigate the combination of NMDA receptor antagonist ketamine and GABAergic agent propofol in an RSE model induced by lithium-pilocarpine in male Sprague-Dawley rats. Seventy-two male Sprague-Dawley rats were divided into nine groups.

View Article and Find Full Text PDF

Design of Ligand-Nonbridging Sites in Metal-Organic Frameworks for Boosting Lithium Storage Capacity.

Angew Chem Int Ed Engl

November 2024

Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, 266237, Qingdao, China.

Metal-organic frameworks (MOFs) are lagging in the use of lithium-ion batteries (LIBs), ascribing to full coordination between metal nodes and organic ligands, to a large extent. By integrating a modulator into a ligand with missing bridging functionality, this study elucidates the role of non-bridging defect sites in MOFs in tailoring lithium storage performance. A fully bridged pristine MOF (p-MOF) utilizing the meso-tetra(4-carboxylphenyl) porphyrin ligand is compared with a modified MOF containing non-bridging defects (d-MOF) introduced by a homologous ligand, tris(4-carboxyphenyl) porphyrin.

View Article and Find Full Text PDF
Article Synopsis
  • Mild traumatic brain injury (mTBI) is common, making up nearly 80% of all brain injuries, and it can cause neurological and cognitive issues even without visible damage.
  • Combining low doses of FDA-approved drugs lithium and valproate after a mild TBI has shown to improve learning and memory, recognizing that these benefits were not observed when either drug was used alone.
  • The treatment also reduced neuroinflammation, suggesting that this combination therapy might help mitigate damage and enhance cognitive function following mild brain injuries.
View Article and Find Full Text PDF

: Glucagon-like peptide-1 receptor agonists such as liraglutide are known for their neuroprotective effects in neurodegenerative disorders, but their role in temporal lobe epilepsy (TLE) remains unclear. We aimed to investigate the effects of liraglutide on several biological processes, including inflammation, antioxidant defense mechanisms, mitochondrial dynamics, and function, as well as cognitive and behavioral changes in the TLE model. : Low-dose, repeated intraperitoneal injections of lithium chloride-pilocarpine hydrochloride were used to induce status epilepticus (SE) in order to develop TLE in rats.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!